Jason McLellan

McLellan and his team collaborated with researchers at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center to design a stabilized version of the SARS-CoV-2 spike protein, which biotechnology company Moderna used as the basis for the vaccine mRNA-1273, the first COVID-19 vaccine candidate to enter phase I clinical trials in the U.S. At least three other vaccines use this modified spike protein: those from Pfizer and BioNTech; Johnson & Johnson and Janssen Pharmaceuticals; and Novavax. According to a June 2022 study published in the Lancet, COVID‑19 vaccines prevented between 14.4 and 19.8 million deaths globally in the first year they were available outside clinical trials. Provided by Wikipedia